Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 382, Issue 13, Pages 1280-1281Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc1913327
Keywords
-
Categories
Funding
- Korea Drug Development Fund
Ask authors/readers for more resources
Telacebec (Q203) is a novel drug that targets Mycobacterium tuberculosis cellular energy production through inhibition of the mycobacterial cytochrome bc1 complex. This proof-of-concept study evaluated the bactericidal activity of telacebec over a period of 14 days in patients with newly diagnosed, drug-susceptible pulmonary tuberculosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
